Clinical Policy: Memantine ER (Namenda XR), Memantine/Donepezil (Namzaric)
Reference Number: CP.PCH.30
Effective Date: 09.01.20
Last Review Date: 08.20
Line of Business: Commercial, HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
The following are agents containing an N-methyl-D-aspartate (NMDA) receptor antagonist and requiring prior authorization: memantine extended-release (Namenda XR®) and memantine/donepezil hydrochloride (Namzaric™).

FDA Approved Indication(s)
Namenda XR and Namzaric are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Namzaric is only indicated in patients stabilized on 10 mg of donepezil hydrochloride once daily.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Namenda XR and Namzaric are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Moderate to Severe Dementia (must meet all):
      1. Diagnosis of moderate to severe dementia;
      2. Age ≥ 18 years;
      3. Failure of donepezil at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
      4. If request is for Namzaric, medical justification supports inability to use the individual generic components of donepezil and memantine;
      5. Dose does not exceed (a or b):
         a. Namenda XR: 28 mg per day;
         b. Namzaric: 28 mg/10 mg per day.
   
   Approval duration:
   Commercial – Length of Benefit
   HIM – 12 months

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is
NOT authorized): CP.CPA.09 for commercial and HIM.PHAR.21 for health insurance marketplace.

II. Continued Therapy

A. Moderate to Severe Dementia (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, new dose does not exceed (a or b):
      a. Namenda XR: 28 mg per day (1 capsule per day);
      b. Namzaric: 28 mg/10 mg per day (1 capsule per day).

   Approval duration:
   Commercial – Length of Benefit
   HIM – 12 months

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and HIM.PHAR.21 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial and HIM.PHAR.21 for health insurance marketplace, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
NMDA: N-methyl-D-aspartate

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>donepezil (Aricept®/Aricept ODT®)</td>
<td>Mild to moderate Alzheimer’s disease: 5 mg to 10 mg PO QD</td>
<td>10 mg/day</td>
</tr>
<tr>
<td></td>
<td>Moderate to severe Alzheimer’s disease: 10 to 23 mg PO QD</td>
<td>23 mg/day</td>
</tr>
</tbody>
</table>
CLINICAL POLICY
Memantine, Memantine/Donepezil

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>memantine (Namenda®)</td>
<td>Moderate to severe Alzheimer’s disease: 5 mg to 20 mg PO QD</td>
<td>20 mg/day</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): known hypersensitivity to memantine hydrochloride (Namenda XR/Namzaric), or donepezil hydrochloride/piperidine derivatives (Namzaric), or to any excipients used in the formulation
- Boxed warning(s): none reported

Appendix D: General Information
- Per the 2007 American Psychiatric Association practice guidelines for the treatment of Alzheimer’s disease, there is modest data that the combination of Namenda and Aricept is better than Aricept alone, and there is no evidence that the combination is better than monotherapy with Namenda.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memantine ER</td>
<td>Initial dose 7 mg PO QD, increase by 7 mg per day at one-week intervals</td>
<td>28 mg/day</td>
</tr>
<tr>
<td>(Namenda XR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memantine/donepezil</td>
<td>Initial dose 7 mg/10 mg PO QD, increased in 7 mg increments per week</td>
<td>28 mg/10 mg/day</td>
</tr>
<tr>
<td>(Namzaric)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memantine ER</td>
<td>Capsule: 7 mg, 14 mg, 21 mg, 28 mg</td>
</tr>
<tr>
<td>(Namenda XR)</td>
<td>Titrination pack: 7 x 7 mg, 7 x 14 mg, 7 x 21 mg, 7 x 28 mg</td>
</tr>
<tr>
<td>Memantine/donepezil</td>
<td>Capsule: 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg, 28 mg/10 mg</td>
</tr>
<tr>
<td>(Namzaric)</td>
<td>Titrination pack: 7 x 7mg/10 mg, 7 x 14mg/10 mg, 7 x 21 mg/10 mg, 7 x 28 mg/10 mg</td>
</tr>
</tbody>
</table>

VII. References


<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created: adapted from previously approved policy (retire CP.CPA.195); added HIM line of business; no significant changes from previously approved policy; references reviewed and updated.</td>
<td>04.20.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a
discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.